Columbia Asset Management’s Vertex Pharmaceuticals VRTX Stock Holding History

Bought
Maintained
Sold
Quarter Market Value Status Shares Change in
Stake
Trade Value Portfolio Weight Portfolio Position
2026
Q2
$1.4M Sell
2,826
-63
-2% -$27.9K 0.24% 77
2026
Q1
$1.29M Buy
2,889
+646
+29% +$301K 0.25% 77
2025
Q4
$1.02M Buy
2,243
+1,690
+306% +$728K 0.18% 88
2025
Q3
$217K Buy
553
+55
+11% +$23K 0.04% 159
2025
Q2
$222K Buy
+498
New +$229K 0.04% 162
2025
Q1
Sell
-802
Closed -$323K 278
2024
Q4
$323K Buy
+802
New +$372K 0.06% 161

Other funds holding VRTX

Columbia Asset Management's VRTX Position: Q2 2026 in Review

Columbia Asset Management reduced its Vertex Pharmaceuticals (VRTX) stake by 2.2% in Q2 2026, selling an estimated $27.9K and leaving 2,826 shares worth $1.4M. The position accounts for 0.24% of the portfolio, ranked #77.

Columbia Asset Management first reported a position in VRTX in Q4 2024 and has held it in 6 quarters since. 1,757 funds tracked by Wall St. Rank hold VRTX as of Q2 2026.

  • Columbia Asset Management held 2,826 shares of Vertex Pharmaceuticals worth $1.4M as of Q2 2026.
  • Columbia Asset Management sold 63 Vertex Pharmaceuticals shares in Q2 2026, an estimated $27.9K.
  • Vertex Pharmaceuticals made up 0.24% of Columbia Asset Management's portfolio in Q2 2026, its #77 holding.
  • Columbia Asset Management first reported a position in Vertex Pharmaceuticals in Q4 2024 and has held it in 6 quarters since.
  • 1,757 funds tracked by Wall St. Rank held Vertex Pharmaceuticals as of Q2 2026.

Based on Columbia Asset Management's 13F filing for Q2 2026, filed 21 Jul 2026.